--- title: Integra Connect | Latest Research description: Supporting life sciences companies’ research, market access and commercial decisions with insights from one of the industry’s most complete and extensive data sets. image: https://campaign.integraconnect.com/hubfs/hexagon-gradient-ipda-stethoscope-min.png --- # Strengthen Real-World Decisions with Real-World Data A growing body of evidence shows Integra Connect solutions can drive success with value-based, precision specialty care [Check out our latest research](https://campaign.integraconnect.com/latest-research#our-latest-research)[Explore our data library](https://campaign.integraconnect.com/latest-research#publications-research) - ### 3.5+ million unique patients lives available for commercial utility - ### 60+ **scientific publications** over the last two years - ### 65+ **engagements **with top pharma, medtech and biotech companies - ### 5000+ **provider relationships**, with the largest footprint of oncology providers focused on value-based care - ### 5 **most prevalent cancers** in our dataset include: breast, colorectal, leukemia, lung and prostate cancers ## Go in-depth with our latest research findings Integra Connect supports life sciences companies’ research, market access and commercial decisions with insights from one of the industry’s most complete and extensive data sets. Meet the experts spearheading our real-world evidence efforts and the insights gathered.  [ Industry Announcement ### ASCO 2023: Integra Connect to Showcase how its Technology and Real-World Data are Helping Deliver on the Promise of Value-based, Precision Oncology *Read Now* ](https://insights.integraconnect.com/news/asco-2023-integra-connect-to-showcase-how-its-technology-and-real-world-data-are-helping-deliver-on-the-promise-of-value-based-precision-oncology?hsLang=en-us) [ Research Feature Blog Post ### ISPOR 2023: New data highlights need for increased EGFR testing in NSCLC; spots alarming gaps for Asian American patients *Read Now* ](https://www.integraconnect.com/blog/ispor-new-data-highlights-need-for-increased-egfr-testing-in-nsclc-spots-alarming-gaps-for-asian-american-patients/) ### WATCH: Real-world Observations Show Beneficial Outcomes in Patients with NSCLC Treated with Pembrolizumab for More than 2 Years Research from NCCN 2023 [Download the Poster](https://campaign.integraconnect.com/hubfs/2023/poster/NCCN_2023.pdf?hsLang=en-us) ## Publications & Research [ publication ### Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy Read more ](https://link.springer.com/article/10.1007/s12325-023-02601-2) [ publication ### Antiemetic use and chemotherapy induced nausea and vomiting related hospitalization costs after highly or moderately emetogenic chemotherapy Read more ](https://www.futuremedicine.com/doi/10.2217/FON-2022-0972) [ publication Quality Initiative ### Understanding testing for and treatment of homologous recombination repair (HRR)-mutated metastatic castrate-resistant prostate cancer (mCRPC): A quality initiative by Integra Connect (IC) PrecisionQ. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e17052) [ publication Quality Initiative ### Management and treatment of patients (pts) with stage III unresected non-small cell lung cancer (NSCLC) at UPMC: A quality initiative by Integra Connect PrecisionQ. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e20588) [ research ### The impact on hospice quality after initiation of an internal palliative care program by a community oncology practice. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e18720) [ publication ### The impact of receipt of systemic anticancer therapy (SACT) near the end of life (EOL) on cost among oncology practices participating in CMS' Oncology Care Model (OCM). Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e18923) [ publication ### PARPi monotherapy as first-line maintenance following chemotherapy + bevacizumab in advanced ovarian cancer. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e17601) [ publication ### Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e17598) [ publication ### Phenotypic differences related to homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) treated in routine care settings in the United States (US). Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e17047) Show More Close [ publication ### Effect of testing for BRCA1/2 on outcomes in patients with ovarian cancer treated with PARPi in 1st line maintenance (1LM). Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e17576) [ publication ### Use of poly (adp-ribose) polymerase inhibitors (PARPi) in metastatic castration resistant prostate cancer (mCRPC) patients stratified by homologous recombination repair mutations. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e17053) [ publication Quality Initiative ### Management and treatment of patients with stage III unresected NSCLC at UPMC: A quality initiative by Integra Connect Precision Q. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e20588) [ publication ### The association between systemic anticancer therapy (SACT) at the end of life (EOL) and acute care use among patients treated at oncology practices participating in the Oncology Care Model (OCM). Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.6580) [ publication ### Real-world testing and treatment patterns among patients with stage IV non-small cell lung cancer: A retrospective observational study. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.9030) [ publication Quality Initiative ### Understanding testing for and treatment of homologous recombination repair (HRR)-mutated metastatic castrate-resistant prostate cancer (mCRPC): A quality initiative by Integra Connect (IC) PrecisionQ. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.e17052) [ publication ### Data driven insights from multiple OCM practices to optimize care for managing high-risk cancer patients across multiple cancer types. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.6576) [ publication Quality Initiative ### Understanding differences in the rates of BRCA/HRD testing and treatment in 1st line maintenance in patients with ovarian cancer treated by gynecologic oncologists compared to other providers: A quality initiative by Integra Connect (IC) PrecisionQ. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2023.41.16_suppl.5576) [ publication ### Validation study of end-of-life risk prediction model in active chemotherapy patients. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2022.40.16_suppl.e13543) [ publication ### Impact of turnaround time (TAT) of molecular testing on initial treatment (Tx) in newly diagnosed stage 4 non-small cell lung cancer (NSCLC 4): An Integra Connect (IC) retrospective observational study Read more ](https://meetings.asco.org/abstracts-presentations/212760) [ publication ### Quality initiative (QI) to improve molecular testing in newly diagnosed (ND) stage 4 non-small cell lung cancer (NSCLC-4): An Integra Connect (IC) database study Read more ](https://meetings.asco.org/abstracts-presentations/212732) [ publication ### Evaluation of outcomes in patients (pts) with stage 4 non-small cell lung cancer (NSCLC 4) harboring actionable oncogenic drivers (AOD) when treated prior to report of mutation without tyrosine kinase inhibitors (TKI): An Integra Connect Database (ICD) retrospective observational study Read more ](https://meetings.asco.org/abstracts-presentations/212395) [ publication ### Real-world treatment patterns and outcomes of triple-exposed multiple myeloma patients treated in community oncology practices in the United States. Read more ](https://meetinglibrary.asco.org/record/199581/abstract) [ publication ### A qualitative analysis of care management based on a large community-based oncology group’s value-based care experience. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2021.39.15_suppl.e18653) [ publication ### Quality initiative (QI) in unresectable stage III non-small cell lung cancer (NCSLC): Impact on time-to-treatment (TTT) for immunotherapy post chemoradiation (CRT). Read more ](https://meetinglibrary.asco.org/record/199620/abstract) [ publication ### The impact of COVID-19 pandemic on access to new patient cancer care as evaluated in the Integra Connect Database (ICD). Read more ](https://meetinglibrary.asco.org/record/199740/abstract) [ research ### A retrospective three-year analysis using real-world data on uptake of broad-based NextGen sequencing panels in community oncology practices. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e13668) [ research ### Impact of cardiologist monitoring on inpatient hospitalizations in breast cancer patients receiving doxorubicin. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e19168) [ publication ### Cost savings of biosimilar pegfilgrastim in a Medicare OCM population. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.e19362#:~:text=Assuming%20that%20the%20patterns%20we,the%20market%20in%20Q4%202018) [ research ### Udenyca has equivalent efficacy to the pegfilgrastim originator in breast cancer patients receiving highly myelosuppressive chemotherapy. Read more ](https://ascopubs.org/doi/10.1200/JCO.2020.38.15_suppl.e19273) [ research ### Real world data analysis of ovarian cancer (OC) maintenance utilization among maintenance eligible patients. Read more ](https://campaign.integraconnect.com/hubfs/Maintenance_Utilization_in_Ovarian_Cancer_ASCO_2019.pdf?hsLang=en-us) [ research ### Genomic testing and treatment landscape in patients with advanced Non-Small Cell Lung cancer (aNSCLC) using real-world data from community oncology practices. Read more ](https://campaign.integraconnect.com/hubfs/Genomic_Testing_and_Treatment_Landscape_in_aNSCLC.pdf?hsLang=en-us) [ research ### A Community Oncology Palliative Program: Early Results for Cost and Quality Measures Within OCM Program Claims Data Read more ](https://campaign.integraconnect.com/hubfs/research/A_Community_Oncology_Palliative_Program.pdf?hsLang=en-us) [ publication ### Payment on the Fast Track. Rooting out the top payment challenges in the value-base care era. Read more ](https://campaign.integraconnect.com/hubfs/Payment-on-the-Fast-Track-Foust-and-Shah-April-2020.pdf?hsLang=en-us) [ research ### Real-world data analysis of immune checkpoint inhibitor utilization by tumor type in the US community oncology setting. Read more ](https://ascopubs.org/doi/abs/10.1200/JCO.2018.36.15_suppl.e15076) [ research ### Patients Receiving Pegfilgrastim via Prefilled Syringe Received Closer CareWhen Compared with On-Body Injector Read more ](https://campaign.integraconnect.com/hubfs/Integra_SABCS-2019.pdf?hsLang=en-us) [ research ### Real World Data Analysis of Ovarian Cancer (OC) Maintenance Utilization Among Maint… Read more ](https://campaign.integraconnect.com/hubfs/ASCO-RWD-analysis-OvCa-poster.pdf?hsLang=en-us) [ research ### A Community Oncology End of Life Care Program: Results for Hospice Length of Stay Analysis Read more ](https://campaign.integraconnect.com/hubfs/A_Community_Oncology_End_of_Life_Care_Program_ASCO_2019.pdf?hsLang=en-us) [ research ### A Community Oncology Palliative Program: Early Results for Cost and Quality… Read more ](https://campaign.integraconnect.com/hubfs/ASCO-palliative-care-2019.pdf?hsLang=en-us) [ research ### Real world duration of maintenance therapy in 2nd-line and later ovarian cancer (OC) Read more ](https://campaign.integraconnect.com/hubfs/Duration_of_Maintenance_Therapy_in_Ovarian_Cancer_ASCO_2019.pdf?hsLang=en-us) [ research ### Automated Clinical Data Preprocessing Accelerates Electronic Case Report Form Comp… Read more ](https://campaign.integraconnect.com/hubfs/ISPOR-abstract-RDTP-eCRF.pdf?hsLang=en-us) [ research ### Healthcare Resource Utilization with Rasburicase in the Management of Patients with Tumor Lysis in the Outpatient Setting: Results from a Community Oncology Cohort Read more ](https://campaign.integraconnect.com/hubfs/ASH2019Poster.pdf?hsLang=en-us) [ research ### Genomic Testing and Treatment Landscape in Patients with Advanced Non-Small Cell… Read more ](https://campaign.integraconnect.com/hubfs/ASCO-abstract-aNSCLC-genetic-testing.pdf?hsLang=en-us) [ research ### The cost of prostate biopsies and their complications: A summary of data on all Medicare fee-for-service patients over two years Read more ](https://campaign.integraconnect.com/hubfs/Poster-AUA-2019-Cost-of-Prostate-Biopsies.pdf?hsLang=en-us) ## Industry Resources [![Untitled design (11)](https://campaign.integraconnect.com/hs-fs/hubfs/Untitled%20design%20(11).png?width=588&name=Untitled%20design%20(11).png) Fierce Biotech White Paper ### Read why healthcare organizations need to make RWD part of their business model Read more ](https://campaign.integraconnect.com/rwd-whitepaper?hsLang=en-us) [![Getting Real About Real-World Data](https://campaign.integraconnect.com/hs-fs/hubfs/ic-tHEORetically-vlog-poster-page.jpg?width=599&name=ic-tHEORetically-vlog-poster-page.jpg) Healtheconomics.com Vlog ### Hear from HEOR Experts - What does RWD and RWE mean to them? Read more ](https://blogsite.healtheconomics.com/2022/11/getting-real-about-real-world-data/) [![Publications Library](https://campaign.integraconnect.com/hs-fs/hubfs/Untitled%20design%20(12).png?width=588&name=Untitled%20design%20(12).png) Integra Connect On-Demand Webinar ### Learn more about tracking quality measures to accelerate precision oncology Read more ](https://insights.integraconnect.com/webinars/tracking-quality-measures-to-accelerate-precision-oncology?hsLang=en-us) Interested in learning more about the findings from Integra Connect Databases? [Schedule time with our experts. Or meet with us at one of our upcoming events.](https://campaign.integraconnect.com/schedule-a-meeting?hsLang=en-us) ## Stay up-to-date on RWD, RWE and HEOR trends with Integra Connect ```json { "@context" : "https://schema.org", "@type" : "VideoObject", "contentUrl" : "https://2389949.fs1.hubspotusercontent-na1.net/hubfs/2389949/NCCN-2023-v2.mp4", "dateModified" : "2023-05-22T15:26:06.991Z", "duration" : "PT1M58S", "height" : 360, "name" : "NCCN-2023-v2", "thumbnailUrl" : "https://api-na1.hubapi.com/filemanager/api/v3/files/thumbnail-redirect/116587403619?portalId=2389949&size=medium", "uploadDate" : "2023-05-22T15:25:59.387Z", "width" : 640 } ```